1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Conflicts between religious institutional directives and state laws for medical aid in dying
    Correspondence

    Guiahi, M.; Epstein, A. S.
    Journal of Palliative Medicine (2020)

    Fulltext@MSK | Save
  • First-in-humans imaging with (89)Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: Preliminary pharmacokinetics, biodistribution, and lesion targeting
    Journal Article

    Pandit-Taskar, N.; Postow, M. A.; Hellmann, M. D.; Harding, J. J.; Barker, C. A.; O'Donoghue, J. A.; Ziolkowska, M.; Ruan, S.; Lyashchenko, S. K.; Tsai, F.; more...
    Journal of Nuclear Medicine (2020)

    Fulltext@MSK | Save
  • Overcoming adaptive resistance to KRAS inhibitors through vertical pathway targeting
    Editorial

    Yaeger, R.; Solit, D. B.
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Phase I study of trifluridine/tipiracil plus irinotecan and bevacizumab in advanced gastrointestinal tumors
    Journal Article

    Varghese, A. M.; Cardin, D. B.; Hersch, J.; Benson, A. B.; Hochster, H. S.; Makris, L.; Hamada, K.; Berlin, J. D.; Saltz, L. B.
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Plasticity in motion: Shape-shifting Lgr5−cells initiate colorectal cancer metastasis
    Journal Article

    Ganesh, K.
    Cell Stem Cell (2020)

    Fulltext@MSK | Save
  • Fight-202: A phase 2 study of pemigatinib in patients (PTS) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)
    Meeting Abstract

    Vogel, A.; Sahai, V.; Hollebecque, A.; Vaccaro, G.; Melisi, D.; Al-Rajabi, R.; Paulson, A. S.; Borad, M. J.; Gallinson, D.; Murphy, A. G.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • POLO: Efficacy and health-related quality of life (HRQOL) with maintenance olaparib following first-line platinum-based chemotherapy (PBC) in patients (PTS) with a germline BRCA mutation and metastatic pancreatic cancer (MPC)
    Meeting Abstract

    Reinacher-Schick, A. C.; Kindler, H. L.; Hammel, P.; Reni, M.; Van Cutsem, E.; Mercade, T. M.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Oh, D. Y.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • BEACON CRC: A randomized, phase 3 study of encorafenib (ENCO) and cetuximab (CETUX) with or without binimetinib (BiNI) vs. choice of either irinotecan or folfiri plus cetux in BRAF V600E-mutant metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Vogel, A.; Hegewisch-Becker, S.; Prager, G.; Folprecht, G.; Stahl, M.; Kopetz, S.; Grothey, A.; van Cutsetn, E.; Yaeger, R.; Wasan, H.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Association of adverse events (AES) with efficacy outcomes for cabozantinib (C) in patients (PTS) with advanced hepatocellular carcinoma (AHCC) in the phase 3 CELESTIAL trial
    Meeting Abstract

    Waidmann, O.; Abou-Alfa, G. K.; Meker, T.; Cheng, A. L.; Cicin, I.; Bolondi, L.; Klumpem, H. J.; Chan, S. L.; Dadduzio, V.; Milwee, S.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Quality-adjusted life years accrued with cabozantinib in patients with advanced hepatocellular carcinoma (AHCC) in the CELESTIAL trial
    Meeting Abstract

    Venerito, M.; Abou-Alfa, G. K.; Mollon, P.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Kelley, R. K.; Baron, A. D.; Benzaghou, F.; Valcheva, V.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save